Literature DB >> 9449699

Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock.

D Aderka1, P Sorkine, S Abu-Abid, D Lev, A Setton, A P Cope, D Wallach, J Klausner.   

Abstract

We examined the kinetics of shedding of the soluble TNF receptors (TNF-Rs) in response to TNF leakage during isolated limb perfusion procedures and correlated them to the resulting hemodynamic effects. Shedding of the TNF-Rs started 7 min after TNF leakage into the systemic circulation. Three waves of shedding were observed peaking at 1, 8-12, and 48-72 h both in vivo and in cell cultures. The soluble receptors prolonged the half-life of TNF in the systemic circulation to 2.5-6 h. Excess shedding of the p75 compared with p55 TNF-Rs was noted during the first wave. The amount and speed of shedding of the p75 TNF-Rs were proportional to the serum TNF levels (P < 0.001). A maximal shedding capacity was attained only during the first wave of shedding, at TNF concentrations of approximately 1.5 ng/ml. Above this level, the linearity between TNF and its soluble receptors was lost. TNF-induced hypotension coincided with the initial imbalance between the concentrations of TNF and its soluble receptors. Despite the spontaneous correction of this imbalance at 8-12 h, the hemodynamic and biochemical alterations persisted and were further aggravated at 18 h, suggesting that other factors induced earlier by TNF are responsible for the perpetuation of the hemodynamic instability. This study may provide the basis for a more physiological therapeutic approach to TNF neutralization in septic shock patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449699      PMCID: PMC508609          DOI: 10.1172/JCI694

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1.

Authors:  R Philip; L B Epstein
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

2.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.

Authors:  P Scheurich; B Thoma; U Ucer; K Pfizenmaier
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

5.  p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

Authors:  E Abraham; M P Glauser; T Butler; J Garbino; D Gelmont; P F Laterre; K Kudsk; H A Bruining; C Otto; E Tobin; C Zwingelstein; W Lesslauer; A Leighton
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

6.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

7.  Isolation and characterization of a tumor necrosis factor binding protein from urine.

Authors:  I Olsson; M Lantz; E Nilsson; C Peetre; H Thysell; A Grubb; G Adolf
Journal:  Eur J Haematol       Date:  1989-03       Impact factor: 2.997

8.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.

Authors:  J L Rothstein; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

9.  Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha.

Authors:  S Yokota; T D Geppert; P E Lipsky
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

10.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  29 in total

Review 1.  Serological markers of disease activity in tuberculosis and HIV infection.

Authors:  A Marchant
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

Review 2.  Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors.

Authors:  Tomohito Gohda; Yasuhiko Tomino
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

3.  Enhanced inflammation with high carbohydrate intake during recovery from eccentric exercise.

Authors:  Chris M Depner; Rochelle D Kirwan; Sara J Frederickson; Mary P Miles
Journal:  Eur J Appl Physiol       Date:  2010-04-03       Impact factor: 3.078

4.  Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes during sepsis limits inflammation through cGMP signaling.

Authors:  Meihong Deng; Patricia A Loughran; Liyong Zhang; Melanie J Scott; Timothy R Billiar
Journal:  Sci Signal       Date:  2015-01-27       Impact factor: 8.192

Review 5.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

6.  Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

Authors:  Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; William Walker; Elizabeth T Rosolowsky; Bijan Roshan; James H Warram; Andrzej S Krolewski
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

7.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

8.  Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.

Authors:  V Gregorc; A Santoro; E Bennicelli; C J A Punt; G Citterio; J N H Timmer-Bonte; F Caligaris Cappio; A Lambiase; C Bordignon; C M L van Herpen
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

9.  Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier.

Authors:  Mohammed F Shamji; Liufang Jing; Jun Chen; Priscilla Hwang; Odelia Ghodsizadeh; Allan H Friedman; William J Richardson; Lori A Setton
Journal:  J Neurosurg Spine       Date:  2008-08

10.  Associations Between Serum Inflammatory Markers and Hippocampal Volume in a Community Sample.

Authors:  Mike F Schmidt; Kevin B Freeman; Beverly G Windham; Michael E Griswold; Iftikhar J Kullo; Stephen T Turner; Thomas H Mosley
Journal:  J Am Geriatr Soc       Date:  2016-08-22       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.